Australia markets closed

Outlook Therapeutics, Inc. (OTLK)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
9.37+0.69 (+7.95%)
At close: 04:00PM EDT
9.37 0.00 (0.00%)
Pre-market: 08:31AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close8.68
Open9.36
Bid9.25 x 200
Ask9.43 x 200
Day's range8.77 - 10.55
52-week range4.00 - 40.60
Volume1,468,111
Avg. volume540,625
Market cap202.245M
Beta (5Y monthly)-0.00
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD

    Positive opinion serves as a basis for final decision for potential authorization from the European Commission (EC), expected within 67 days ISELIN, N.J., March 22, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the US and the EU, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European M

  • GlobeNewswire

    Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million

    ISELIN, N.J., March 18, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the US and the EU, today announced that it has closed its previously announced private placement, for upfront gross proceeds of approximately $60 million from the issuance and sale of shares of the Company’s common stock and accompanying warrants, before d

  • GlobeNewswire

    Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split

    ISELIN, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation of bevacizumab for the treatment of retinal diseases, today announced that a 1-for-20 reverse stock split of its outstanding shares of common stock will be effective on March 14, 2024. The Company’s common stock will begin trading on a reverse stock split-adjusted basis at the opening of the ma